Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells. (November 2022)

• Record Type: Journal Article
• Authors: Tumino, Nicola; Fiore, Piera Filomena; Pelosi, Andrea; Moretta, Lorenzo; Vacca, Paola
• Is Part Of: Seminars in immunology. Volume 61/64(2022)
• Publication Date: 2022-11
• Subjects: ADCC antibody-dependent cellular cytotoxicity -- ARG-1 arginase-1 -- BM Bone marrow -- C/EBPβ CCAAT-enhancer-binding protein beta -- c-kit receptor tyrosine kinase -- COX-2 cyclooxygenase -- DC Dendritic cells -- DNAM-1 DNAX accessory molecule-1 -- e-MDSC early-MDSC -- EMT epithelial to mesenchymal transition -- EOMES Eomesodermin -- FLT3 ligand FMS-like tyrosine kinase 3 ligand -- G-CSF granulocytes-colony stimulating factor -- GM-CSF granulocytes-macrophage-CSF -- HLA human leukocyte antigen -- IDO indoleamine 2, 3-dioxygenase -- IFN interferon -- IL- interleukin -- ILC innate lymphoid cells -- IMC immature myeloid cells -- iNOS inducible nitric oxide synthase -- KIR killer Ig-like receptors -- LOX-1 lectin-type oxidized LDL receptor-1 -- LPS lipopolysaccharide -- LTi lymphoid tissue inducer cells -- M-CSF macrophage-CSF -- MDSC Myeloid derived suppressor cells -- M-MDSC Mononucear-MDSC -- MMP9 metalloproteases 9 -- NB neuroblastoma -- NCR natural cytotoxic receptors -- NK Natural Killer cells -- NOX2 NADPH oxidase 1 -- PB peripheral blood -- PD-1 program death-1 -- PGE2 prostaglandin E2 -- PMN-MDSC Polymorphonuclear-MDSC -- ROS reactive oxygen species -- SLO secondary lymphoid organs -- STAT3 signal transducer and activator of transcription 3 -- T-bet T-box protein expressed in T cells -- TF transcription factor -- TGF-β tumor growth factor beta -- TIGIT T cell immunoreceptor with Ig and ITIM domains -- TIM-3 T cell immunoglobulin and mucin-domain containing-3 -- TME Tumor microenvironment -- TNF Tumor necrosis factor -- TPO Thyroid peroxidase -- Treg Regulatory T cells -- TSLP tymic stromal lymphoprotein -- VEGF vascular endothelial growth factor; Myeloid-derived suppressor cells -- Innate Lymphoid Cells -- Tumor microenvironment -- Immunotherapy -- Tumor; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Immunity -- Periodicals; Immunologie -- Périodiques; Electronic journals; 616.079
• DOI: 10.1016/j.smim.2022.101668
• Languages: English
• ISSNs: 1044-5323

Abstract

Abstract: Human myeloid-derived suppressor cells (MDSC) represent a stage of immature myeloid cells and two main subsets can be identified: monocytic and polymorphonuclear. MDSC contribute to the establishment of an immunosuppressive tumor microenvironment (TME). The presence and the activity of MDSC in patients with different tumors correlate with poor prognosis. As previously reported, MDSC promote tumor growth and use different mechanisms to suppress the immune cell-mediated anti-tumor activity. Immunosuppression mechanisms used by MDSC are broad and depend on their differentiation stage and on the pathological context. It is known that some effector cells of the immune system can play an important role in the control of tumor progression and metastatic spread. In particular, innate lymphoid cells (ILC) contribute to control tumor growth representing a potential, versatile and, immunotherapeutic tool. Despite promising results obtained by using new cellular immunotherapeutic approaches, a relevant proportion of patients do not benefit from these therapies. Novel strategies have been investigated to overcome the detrimental effect exerted by the immunosuppressive component of TME (i.e. MDSC). In this review, we summarized the characteristics and the interactions occurring between MDSC and ILC in different tumors discussing how a deeper knowledge on MDSC biology could represent an important target for tumor immunotherapy capable of decreasing immunosuppression and enhancing anti-tumor activity exerted by immune cells.